Madrigal Pharmaceuticals (MDGL) had the highest return in 2022 by a US stock in the Biotechnology Industry, returning 238.1%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Madrigal Pharmaceuticals (MDGL) | 2022 | 238.09% |
Rhythm Pharmaceuticals (RYTM) | 2022 | 191.2% |
ADMA Biologics (ADMA) | 2022 | 177.14% |
Catalyst Pharmaceuticals (CPRX) | 2022 | 173.93% |
Ardelyx (ARDX) | 2022 | 154.46% |
Jade Biosciences (JBIO) | 2022 | 141.75% |
Cabaletta Bio (CABA) | 2022 | 141.51% |
Belite Bio Inc ADR (BLTE) | 2022 | 141.16% |
Biohaven Pharmaceutical (BHVN) | 2022 | 131.33% |
Voyager Therapeutics (VYGR) | 2022 | 123.44% |
Fennec Pharmaceuticals (FENC) | 2022 | 118.68% |
Capstone Holding Corp Common Stock (CAPS) | 2022 | 114.49% |
Immunovant (IMVT) | 2022 | 107.36% |
Vaxcyte (PCVX) | 2022 | 101.47% |
Viking Therapeutics (VKTX) | 2022 | 101.28% |
Geron (GERN) | 2022 | 96.75% |
Nuvectis Pharma (NVCT) | 2022 | 89.87% |
Actinium Pharmaceuticals (ATNM) | 2022 | 76.91% |
Altimmune (ALT) | 2022 | 75.37% |
Aldeyra (ALDX) | 2022 | 71.43% |
Biovie (BIVI) | 2022 | 65.67% |
Summit Therapeutics (SMMT) | 2022 | 64.03% |
Immunocore (IMCR) | 2022 | 63.84% |
Protalix Biotherapeutics (PLX) | 2022 | 63.1% |
Arcellx (ACLX) | 2022 | 63.05% |
